FY2026 EPS Estimate for EUDA Health Decreased by Analyst

EUDA Health Holdings Limited (NASDAQ:EUDA) – Equities researchers at Greenridge Global reduced their FY2026 EPS estimates for shares of EUDA Health in a research report issued on Monday, March 9th. Greenridge Global analyst W. Gregozeski now expects that the company will post earnings of $0.08 per share for the year, down from their previous forecast of $0.17. Greenridge Global currently has a “Buy” rating and a $2.75 target price on the stock. The consensus estimate for EUDA Health’s current full-year earnings is ($0.33) per share.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of EUDA Health in a report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, EUDA Health currently has a consensus rating of “Hold” and an average target price of $2.75.

EUDA Health Trading Down 1.7%

Shares of EUDA Health stock opened at $0.50 on Wednesday. The stock’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $2.00. The company has a market capitalization of $18.98 million, a PE ratio of -4.18 and a beta of -0.11. EUDA Health has a 12 month low of $0.46 and a 12 month high of $4.30.

Institutional Investors Weigh In On EUDA Health

An institutional investor recently bought a new position in EUDA Health stock. Jane Street Group LLC purchased a new position in shares of EUDA Health Holdings Limited (NASDAQ:EUDA) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 25,675 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 0.07% of EUDA Health as of its most recent SEC filing. Hedge funds and other institutional investors own 4.35% of the company’s stock.

About EUDA Health

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.